SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-24-100817
Filing Date
2024-04-18
Accepted
2024-04-18 16:21:56
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A d754140ddefa14a.htm DEFA14A 19011
2 GRAPHIC g754140dsp02.jpg GRAPHIC 262137
3 GRAPHIC g754140dsp02a.jpg GRAPHIC 151522
4 GRAPHIC g754140dsp03.jpg GRAPHIC 1652
  Complete submission text file 0001193125-24-100817.txt   592452
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39536 | Film No.: 24854564
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)